Short answer
PALVELLA THERAPEUTICS, INC. (PVLA) filed an 8-K current report with the SEC on August 4, 2026 reporting Item EX-99.1 (Exhibit EX-99.1), Item EX-99.2 (Exhibit EX-99.2), Item 7.01 (Regulation FD Disclosure), Item 2.02 (Results of Operations and Financial Condition). Q2 2026 financial results announced for quarter ended June 30, 2026.
PALVELLA THERAPEUTICS, INC. 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Q2 2026 financial results announced for quarter ended June 30, 2026
- Investor focus: Exhibit 99.1 contains the reported financial figures and management commentary
- Results update may inform liquidity, development spending and clinical-program funding runway
Item 7.01 · Regulation FD Disclosure
- August 4, 2026 earnings call supported by investor slide presentation
- Exhibit 99.2 contains presentation materials, offering additional context for the earnings update
Item EX-99.1 · Exhibit EX-99.1
- Q2 2026 results: $21.9M net loss, or $1.52 per share, versus $9.5M and $0.86 in Q2 2025
- Cash, equivalents and short-term investments of $250.6M support ongoing clinical development and planned commercialization activities
- Rolling NDA for QTORIN rapamycin in microcystic lymphatic malformations initiated, with completion targeted for second half 2026
- Planned standalone U.S. launch in first half 2027 remains contingent on FDA approval
- R&D spending rose to $12.5M from $5.1M, reflecting NDA preparation, manufacturing and expanded clinical programs
Item EX-99.2 · Exhibit EX-99.2
- Q2 2026 update: NDA rolling review granted, first module submitted June 2026, full submission targeted for 2H 2026
- QTORIN™ Phase 3 initiation for microcystic lymphatic malformations remains on track for Q4 2026, supporting potential 1H 2027 approval
- Cash $251M as of June 30, 2026, with anticipated 2026 cash expenses of $85M-$95M
- Cutaneous venous malformation Phase 3 initiation targeted for Q4 2026 after planned end-of-Phase 2 meeting
- Pipeline expansion: DSAP Phase 2 initiation planned for 2H 2026, angiokeratoma topline results expected in 2H 2027
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other PALVELLA THERAPEUTICS, INC. 8-K filings
Get the next PVLA 8-K as it lands
Follow PVLA for push alerts, or ask the research agent what this filing means.